U.S. President Donald Trump to speak to Congress
U.S. President Donald Trump is set to deliver a speech to Congress tonight.
The speech, scheduled to start at 9 p.m. ET, is not an official State of the Union speech, but it will be the president's first major address since his return to Washington.
It will also be his first time speaking publicly since he launched a trade war against America's three largest trading partners.
The theme of the speech is "Renewal of the American Dream," according to the White House.
CBC News will have special coverage of the speech with chief correspondent Adrienne Arsenault, starting at 8 p.m. ET.
Trump is expected to lay out his plans for the American people over the next weeks and months after an intense start to his second term, which has seen the president prove his willingness to cast aside longstanding diplomatic relationships in favour of the "America first" vision for his administration.
No relationship was targeted more swiftly than the one with Canada.
The president's crushing tariffs on virtually all of the Canadian goods flowing into the United States came into effect on Tuesday despite Ottawa's attempts to placate the president over the last 30 days. Canada swung back with its own tariffs on $30 billion worth of American goods, driving a stake firmly between two typically-kindred nations.
Earlier Tuesday, Prime Minister Justin Trudeau described Trump's decision as a "very dumb" move. He said he was at a loss as to why the American president would go after an ally, but said he suspects he wants to hit the Canadian economy in the back of the knees because he believes that will make the country easier to absorb.
"He can do damage to the Canadian economy but he is going to rapidly find out, as American families are going to rapidly find out, it's going to hurt people on both sides of the border," Trudeau said.
The tariffs had a profound and immediate effect Tuesday, upending diplomatic relationships and rattling global financial markets. Economists have warned the trade war could increase inflation.
Some Democratic lawmakers said they would skip Trump's speech to Congress. First lady Melania Trump will be joined at the address by selected guests, including the family of Corey Comperatore, a firefighter killed by the gunman who grazed Trump with a bullet during a campaign rally in Butler, Pa., last July.
Other Democratic lawmakers reportedly plan to wear blue and yellow scarves to show support for Ukraine, which is no longer receiving military aid from the U.S. after a meeting between the two nations' leaders unravelled at the White House last Friday.
WATCH | Canada's finance minister on the government's plans for the trade war:
We saw this trade war coming. How has Canada prepared?
51 minutes ago
Duration 10:00
As the U.S. imposes 25 per cent tariffs on all Canadian goods, The National's Adrienne Arsenault asks Finance Minister Dominic LeBlanc about what the federal government is doing to cushion the effects of the tariffs and how it will respond to a trade war.
Trump and U.S. Vice-President J.D. Vance berated Ukraine President Volodymyr Zelenskyy inside the Oval Office, speaking loudly over the European leader as they called him "disrespectful" and said he had been ungrateful for American aid.
Trump tried to pressure Zelenskyy to agree to negotiating a peace deal with Russia, the nation that invaded his own three years ago. On Monday, Zelenskyy said on X that the meeting was "regrettable" and that he intended to "make things right."
Throughout his campaign, Trump made clear that a second presidency would see him crack down on other nations he perceived as taking advantage of the United States.
He has threatened to annex Canada as the 51st state, seize Greenland from Denmark and take back control of the Panama Canal.
In addition to freezing military aid for Ukraine, he also cut off foreign aid to countries in other parts of the world. He went ahead with tariffs on goods from China, Mexico and Canada, despite Ottawa's attempts to placate the president over the last 30 days.
Those moves and intentions align with the theme of Trump's inaugural address on Jan. 20.
"America will reclaim its rightful place as the greatest, most powerful, most respected nation on Earth, inspiring the awe and admiration of the entire world," Trump said in that speech.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
an hour ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む
Toronto Star
an hour ago
- Toronto Star
Competition Bureau seeking public input on algorithmic pricing
OTTAWA - The Competition Bureau says it's looking for public input as it delves deeper into the rising trend of companies using algorithms to set prices. In a paper released Tuesday, the bureau says more than 60 companies in Canada already use automated systems to help set prices, often in real time, for everything from concert tickets to ridesharing to hotel rooms. The paper says that algorithmic pricing could improve competition by helping businesses innovate and be more efficient, but also risks making it easier for companies to co-ordinate their prices and could make it harder for new companies to enter the market. ARTICLE CONTINUES BELOW It says algorithmic pricing could become an issue under the Competition Act if multiple companies rely on the same model to set pricing, creating a form of collusion on pricing even without explicit collaboration. The bureau says the systems could also be used for predatory pricing if a company uses them to specifically target specific customers of rivals, rather than lowering prices overall. The Competition Bureau confirmed in February that it was also investigating the possible use of AI-driven algorithmic pricing in Canadian real estate rental markets. This report by The Canadian Press was first published June 10, 2025.
Toronto Star
an hour ago
- Toronto Star
Los Angeles imposes downtown curfew as protests against Trump's immigration crackdown continue
LOS ANGELES (AP) — Los Angeles leaders imposed a downtown curfew through Wednesday morning to deal with protests against President Donald Trump's immigration crackdown, while the governor accused him of drawing a 'military dragnet' across the nation's second-largest city with his escalating use of the National Guard. Democratic Gov. Gavin Newsom asked a court to put an emergency stop to the military helping federal immigration agents, with some guardsmen now standing in protection around agents as they carried out arrests. He said it would only heighten tensions and promote civil unrest. The judge chose not to rule immediately, giving the administration several days to continue those activities before a hearing Thursday.
